Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 508 of 1,261
  1. US 10246514

    Single domain antibodies that bind to human CD20

    United States of America as represented by the Secretary of the Air Force · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted
  2. US 10246709

    Targeting ligands for therapeutic compounds

    Arrowhead Pharmaceuticals, Inc. · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted
  3. US 10246708

    Dosages and methods for delivering lipid formulated nucleic acid molecules

    Alnylam Pharmaceuticals, Inc. · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted
  4. US 10246509

    Restricted immunoglobulin heavy chain mice

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted
  5. US 10246505

    Chimeric antigen receptors to control HIV infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted
  6. US 10246471

    ETP derivatives

    The Regents of the University of California · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted
  7. US 10246453

    Benzenesulfonamide compounds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted
  8. IT 201700108526

    COMPOSIZIONI ORALI PER IL TRATTAMENTO DEL REFLUSO GASTROESOFAGEO.

    ALFASIGMA SPA [IT] · Granted Mar 28, 2019 · Expires Mar 23, 2039

    granted
  9. US 10239911

    Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  10. US 10238652

    Compounds for treatment of cancer

    Curegenix, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  11. US 10238698

    Biomarkers and combination therapies using oncolytic virus and immunomodulation

    The Board of Regents of the University of Texas System · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  12. US 10240130

    CDNA clone-launched platform for high-yield production of inactivated zika virus

    The Board of Regents of the University of Texas System · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  13. US 10239832

    N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  14. US 10238710

    Peptide having anti-inflammatory, osteogenic and hair growth promoting activities, and use of same

    CAREGEN CO., LTD. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  15. US 10240157

    Diagnostic and screening methods for atopic dermatitis

    The Regents of the University of California · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  16. US 10240152

    Compositions and methods for inhibiting expression of transthyretin

    Alnylam Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  17. US 10240153

    Organic compositions to treat APOC3-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  18. US 10240149

    Reduced size self-delivering RNAi compounds

    Phio Pharmaceuticals Corp. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  19. US 10239954

    Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer

    The Regents of the University of California · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  20. US 10239949

    Oncofetal antigen binding proteins and related compositions and methods

    Aptevo Research and Development LLC · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  21. US 10239912

    Modulators of 5′-nucleotidase, ecto and the use thereof

    Arcus Biosciences, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  22. US 10239918

    Cahuitamycins and methods of making and using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  23. US 10238770

    Reparative cell isolation and delivery

    The Board of Regents of the University of Texas System · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  24. US 10239837

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.